부산대학교 도서관

Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024. Keywords: chronic obstructive pulmonary disease, therapy, phosphodiesterase inhibitor
Introduction Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder of the respiratory system which is characterized by irreversible airflow obstruction, remodeling of the airways and acute exacerbations leading [...]